A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib

Leuk Res. 2010 Sep;34(9):e240-2. doi: 10.1016/j.leukres.2010.03.036. Epub 2010 May 5.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Dasatinib
  • Female
  • Genes, abl*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Mutation*
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Pyrimidines
  • Thiazoles
  • Dasatinib